



## Richard Elliot DOBLIN

**ORCID ID:** 0001-7361-8168

**Position Title:** Founder and President

### **ORGANIZATION AND LOCATION**

**Name:** Multidisciplinary Association of Psychedelic Studies (MAPS)

**Location:** 3141 Stevens Creek Blvd #40563, San Jose, CA 95117

### **PROFESSIONAL PREPARATION**

**Harvard University, John F. Kennedy School of Government** Cambridge, Massachusetts, United States Ph.D., Public Policy; Master of Public Policy Start Date: 1991 End Date: 2001

**New College of the University of South Florida** Sarasota, Florida, United States Bachelor of Arts, Psychology Start Date: 1971 End Date: 1972

Start Date: 1982 End Date: 1987

### **PRODUCTS**

**Doblin, R.** (2019). The Future of Psychedelic-Assisted Therapy. TED Talk.

[https://www.ted.com/talks/rick\\_doblin\\_the\\_future\\_of\\_psychedellic\\_assisted\\_psychotherapy](https://www.ted.com/talks/rick_doblin_the_future_of_psychedellic_assisted_psychotherapy)

Product Type: Website / Educational Resource

**Doblin, R.** (2020). Rick Doblin: Origin Story. MAPS.

[https://www.youtube.com/watch?v=4s\\_j2OJOhrI](https://www.youtube.com/watch?v=4s_j2OJOhrI) Product Type: Website / Narrative History

**Doblin, R.** (2001). *Regulation of the Medical Use of Psychedelics and Marijuana*. Doctoral Dissertation, Harvard University, Graduate School of Education.

<https://maps.org/research-archive/dissertation/dissertation.pdf>

Product Type: Doctor of Philosophy (Ph.D.), Public Policy, Harvard University

### Publications

van der Kolk, B. A., Wang, J. B., Yehuda, R., Bedrosian, L., Coker, A. R., Harrison, C., Mithoefer, M., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2024). Effects of MDMA-assisted therapy for PTSD on self-experience. *PLOS ONE*, 19(1), e0295926.

<https://doi.org/10.1371/journal.pone.0295926>

Mitchell, J. M., Ot'abora G, M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., **Doblin, R.**, Yazar-Klosinski, B., Garas, W., May, D., Marta, C., Walker, S., Nielson, E., Wells, G., Brown, R., Amiaz, R., Wallach, Y., Worthy, R., Lilienstein, A., & Emerson, A. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. *Nature Medicine*, 29(10), 2473–2480. <https://doi.org/10.1038/s41591-023-02565-4>

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'abora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., Amiaz, R., Worthy, R., Shannon, S., Woolley, J. D., Marta, C., Gelfand, Y., Hapke, E., Amar, S., Wallach, Y., Brown, R., Hamilton, S., Wang, J. B., Coker, A., Matthews, R., de Boer, A., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2023). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. *Focus (American Psychiatric Publishing)*, 21(3), 315–328. <https://doi.org/10.1176/appi.focus.23021011>

Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & **Doblin, R.** (2023). Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. *Focus (American Psychiatric Publishing)*, 21(3), 306–314. <https://doi.org/10.1176/appi.focus.23021013>

Singleton, S. P., Wang, J. B., Mithoefer, M., Hanlon, C. A., George, M. S., Mithoefer, A. T., Mithoefer, O., Coker, A. R., Yazar-Klosinski, B., Emerson, A., Kuceyeski, A., & **Doblin, R.** (2023). Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. *Frontiers in Psychiatry*, 13, Article 947622.

<https://doi.org/10.3389/fpsy.2022.947622>

Barnett, B. S., Ziegler, K., **Doblin, R.**, & Carlo, A. D. (2022). Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data. *Journal of Psychopharmacology*, 36(10), 1118–1128. <https://doi.org/10.1177/02698811221117536>

Ching, T. H., Williams, M. T., Wang, J. B., Jerome, L., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2022). MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnorracial differences in efficacy and safety from two phase 2 open-label lead-in trials and a

phase 3 randomized, blinded placebo-controlled trial. *Journal of Psychopharmacology*, 36(8), 974–986. <https://doi.org/10.1177/02698811221104052>

Ching, T. H. W., Williams, M. T., Reed, S. J., Kisicki, M. D., Wang, J. B., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2022). MDMA-assisted therapy for posttraumatic stress disorder: A mixed-methods case study of a participant of color from an open-label trial. *Journal of Humanistic Psychology*. <https://doi.org/10.1177/00221678221076993>

Brewerton, T. D., Wang, J. B., Lafrance, A., Pamplin, C., Mithoefer, M., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2022). MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. *Journal of Psychiatric Research*, 149, 128–135. <https://doi.org/10.1016/j.jpsychires.2022.03.008>

Nicholas, C. R., Wang, J. B., Coker, A., Mitchell, J. M., Klaire, S. S., Yazar-Klosinski, B., Emerson, A., Brown, R. T., & **Doblin, R.** (2022). The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. *Drug and Alcohol Dependence*, 233, 109356. <https://doi.org/10.1016/j.drugalcdep.2022.109356>

Barnett, B. S., Beaussant, Y., King, F., IV, & **Doblin, R.** (2022). Psychedelic knowledge and opinions in psychiatrists at two professional conferences: An exploratory survey. *Journal of Psychoactive Drugs*, 54(3), 269–277. <https://doi.org/10.1080/02791072.2021.1957183>

Wang, J. B., Lin, J., Bedrosian, L., Coker, A., Jerome, L., Feduccia, A., Lilienstein, A., Harrison, C., Heimler, E., Mithoefer, M., Mithoefer, A., O’alora G., M., Poulter, B., Carlin, S., Matthews, R., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2021). Scaling up: Multisite open-label clinical trials of MDMA-assisted therapy for severe posttraumatic stress disorder. *Journal of Humanistic Psychology*. <https://doi.org/10.1177/00221678211023663>

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., O’alora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., Amiaz, R., Worthy, R., Shannon, S., Woolley, J. D., Marta, C., Gelfand, Y., Hapke, E., Amar, S., Wallach, Y., Brown, R., Hamilton, S., Wang, J. B., Coker, A., Matthews, R., de Boer, A., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. *Nature Medicine*, 27(6), 1025–1033. <https://doi.org/10.1038/s41591-021-01336-3>

Roseman, L., Ron, Y., Saca, A., Ginsberg, N., Luan, L., Karkabi, N., **Doblin, R.**, & Carhart-Harris, R. (2021). Relational processes in ayahuasca groups of Palestinians and Israelis. *Frontiers in Pharmacology*, 12, 607529. <https://doi.org/10.3389/fphar.2021.607529>

Bonn-Miller, M. O., Sisley, S., Riggs, P., Yazar-Klosinski, B., Wang, J. B., Loflin, M. J. E., Shechet, B., Hennigan, C., Matthews, R., Emerson, A., & **Doblin, R.** (2021). The short-term impact of three smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. *PLOS ONE*, 16(3), e0246990. <https://doi.org/10.1371/journal.pone.0246990>

Mithoefer, M. C., Mithoefer, A., Feduccia, A., Jerome, L., Wagner, M., Holland, F., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2019). MDMA-assisted psychotherapy for PTSD: A promising novel experimental treatment moving into phase 3 trials with FDA breakthrough therapy designation. *European Neuropsychopharmacology*, 29, S11–S12. <https://doi.org/10.1016/j.euroneuro.2018.11.930>

Hake, H., Davis, J., Wood, R., Tanner, M., Loetz, E. C., Sanchez, A., Ostrovsky, M., Oleson, E. B., Grigsby, J., **Doblin, R.**, & Greenwood, B. (2018). 3,4-Methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. *Physiology & Behavior*, 199. <https://doi.org/10.1016/j.physbeh.2018.12.007>

Ot'abora G., M., Grigsby, J., Poulter, B., Van Derveer, J. W., III, Giron, S. G., Jerome, L., Feduccia, A. A., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & **Doblin, R.** (2018). MDMA-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. *Journal of Psychopharmacology*, 32(12). <https://doi.org/10.1177/0269881118806>

Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & **Doblin, R.** (2018). MDMA-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomized, double-blind, dose-response, phase 2 clinical trial. *The Lancet Psychiatry*, 5(6), 486–497. [https://doi.org/10.1016/S2215-0366\(18\)30135-4](https://doi.org/10.1016/S2215-0366(18)30135-4)

Feduccia, A. A., Mithoefer, M. C., Jerome, L., Holland, J., Emerson, A., & **Doblin, R.** (2017). Response to the consensus statement of the PTSD psychopharmacology working group. *Biological Psychiatry*. <https://doi.org/10.1016/j.biopsych.2017.11.023>

Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T., MacAulay, R. K., Jerome, L., Yazar-Klosinski, B., & **Doblin, R.** (2017). Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. *Journal of Psychopharmacology*, 31(8), 967–974. <https://doi.org/10.1177/0269881117711712>

Gasser, P., Holstein, D., Michel, Y., **Doblin, R.**, Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of LSD-assisted psychotherapy in participants with anxiety associated with life-threatening diseases: A randomized active placebo-controlled phase 2 pilot study. *Journal of Nervous and Mental Disease*, 202, 513–520. <https://doi.org/10.1097/NMD.0000000000000113>

**Doblin, R.**, Greer, G., Holland, J., Jerome, L., Mithoefer, M. C., & Sessa, B. (2014). A reconsideration and response to Parrott (2013). *Human Psychopharmacology*, 29(2), 105–108. <https://doi.org/10.1002/hup.2389>

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & **Doblin, R.** (2013). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after

MDMA-assisted psychotherapy. *Journal of Psychopharmacology*, 27(1), 28–39. <https://doi.org/10.1177/0269881112456611>

Mithoefer, M., Wagner, M., Mithoefer, A., Jerome, L., & **Doblin, R.** (2010). The safety and efficacy of MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant PTSD. *Journal of Psychopharmacology*. <https://doi.org/10.1177/0269881110378371>

Bouso, J. C., **Doblin, R.**, Farré, M., Alcázar, M. A., & Gómez-Jarabo, G. (2008). MDMA-assisted psychotherapy using low doses in women with chronic PTSD. *Journal of Psychoactive Drugs*, 40(3), 225–236. <https://doi.org/10.1080/02791072.2008.10400637>

Mithoefer, M., Jerome, L., & **Doblin, R.** (2003). MDMA (“ecstasy”) and neurotoxicity. *Science*, 300, 1504. <https://doi.org/10.1126/science.300.5625.1504>

**Doblin, R.** (2002). A clinical plan for MDMA in the treatment of PTSD: Partnering with the FDA. *Journal of Psychoactive Drugs*, 34(2), 185–194. <https://doi.org/10.1126/science.300.5625.1504>

Grinspoon, L., & **Doblin, R.** (2001). Psychedelics as catalysts of insight-oriented psychotherapy. *Social Research*, 68(3), 677–698. <https://www.scribd.com/document/344525869/Psychedelics-as-Catalysts-of-Insight-Oriented-Psychotherapy>

**Doblin, R.** (1998). Dr. Leary’s Concord Prison Experiment: A 34-year follow-up. *Journal of Psychoactive Drugs*, 30(4), 419–426. <https://doi.org/10.1080/02791072.1998.10399715>

**Doblin, R.**, & Kleiman, M. (1998). Survey research vs. clinical trials in evaluating the medical utility of marijuana. *Southern Medical Journal*, 91(10), 989–991. <https://doi.org/10.1097/00007611-199810000-00032>

**Doblin, R.**, & Kleiman, M. (1995). The medical use of marijuana: The case for clinical trials. *Journal of Addictive Diseases*, 14(1), 5–14. [https://doi.org/10.1300/J069v14n01\\_02](https://doi.org/10.1300/J069v14n01_02)

**Doblin, R.** (1991). Pahnke’s Good Friday experiment: A long-term follow-up and methodological critique. *Journal of Transpersonal Psychology*, 23(1), 1–28. <https://atpweb.org/jtparchive/trps-23-91-01-001.pdf>

**Doblin, R.**, & Kleiman, M. (1991). Marijuana as antiemetic medicine: A survey of oncologists’ experiences and attitudes. *Journal of Clinical Oncology*, 9(7), 1314–1319. <https://doi.org/10.1200/jco.1991.9.7.1314>

**Doblin, R.**, & Kleiman, M. (1991). The medical use of marijuana. *Annals of Internal Medicine*, 114(9), 809–810. [https://doi.org/10.7326/0003-4819-114-9-809\\_3](https://doi.org/10.7326/0003-4819-114-9-809_3)